Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225410 | 0.79 | CA12 (0.47) | TLR8CA2CA1CA9CA5A | |
| SCHEMBL437855 | 0.78 | F2 (0.43) | TLR8ALOX15F2F10MAPT | |
| SCHEMBL12117962 | 0.76 | MAPT (0.46) | STSTLR8CA2CA1CA9 | |
| SCHEMBL284155 | 0.75 | TLR8 (0.50) | STSTLR8CA2ALOX15F2 | |
| SCHEMBL18067895 | 0.75 | S1PR1 (0.44) | TLR8F2F10S1PR1 | |
| SCHEMBL436265 | 0.74 | S1PR1 (0.41) | TLR8CA2CA9ALOX15F2 | |
| Hydrochloric Acid SCHEMBL5395881 | 0.74 | TLR8 (0.52) | STSTLR8CA2ALOX15F2 | |
| SCHEMBL12370192 | 0.73 | TLR8 (0.44) | TLR8CA2CA1CA9CA5A | |
| SCHEMBL457899 | 0.73 | ALOX15 (0.39) | STSTLR8ALOX15F2F10 | |
| SCHEMBL282809 | 0.73 | NPC1 (0.43) | STSALOX15HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312345-B2 | Process for the preparation of dronedarone | ISP INVESTMENTS INC. (US) | 2007-12-25 | — | — | US | claimed |
| CN-115521277-A | Method for preparing benzofuran compound | 山东新时代药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| US-8816103-B2 | Process for the preparation of dronedarone | SANOFI (FR) | 2014-08-26 | — | — | US | disclosed |
| EP-2595978-A1 | NOVEL PROCESS FOR THE PREPARATION OF DRONEDARONE | SANOFI (FR) | 2013-05-29 | — | — | EP | disclosed |
| US-20130131358-A1 | Novel Process for the Preparation of Dronedarone | SANOFI (FR) | 2013-05-23 | — | — | US | disclosed |
| WO-2012010913-A1 | NOVEL PROCESS FOR THE PREPARATION OF DRONEDARONE | SANOFI (FR) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131358-A1 | Novel Process for the Preparation of Dronedarone | CYP2F1, CYP3A4, CYP2D6 | STS 224/4885TLR8 4747/4885CA2 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.